Predictive Oncology (NASDAQ:POAI) Trading Down 5%

Shares of Predictive Oncology Inc. (NASDAQ:POAI) dropped 5% during trading on Monday . The stock traded as low as $0.96 and last traded at $0.96. Approximately 894,506 shares were traded during trading, a decline of 72% from the average daily volume of 3,203,570 shares. The stock had previously closed at $1.01.

Separately, HC Wainwright initiated coverage on shares of Predictive Oncology in a report on Wednesday, June 30th. They set a “buy” rating and a $5.00 target price on the stock.

The firm has a market cap of $62.79 million, a P/E ratio of -0.74 and a beta of 2.00. The business’s fifty day simple moving average is $1.09 and its 200-day simple moving average is $1.17.

Predictive Oncology (NASDAQ:POAI) last announced its quarterly earnings results on Wednesday, August 11th. The medical instruments supplier reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. Predictive Oncology had a negative net margin of 1,725.34% and a negative return on equity of 43.92%. Sell-side analysts predict that Predictive Oncology Inc. will post -0.25 EPS for the current year.

Several large investors have recently bought and sold shares of POAI. Armistice Capital LLC purchased a new stake in shares of Predictive Oncology in the 1st quarter worth about $2,482,000. Vanguard Group Inc. lifted its position in shares of Predictive Oncology by 231.9% in the 2nd quarter. Vanguard Group Inc. now owns 1,838,085 shares of the medical instruments supplier’s stock worth $2,408,000 after purchasing an additional 1,284,326 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Predictive Oncology in the 1st quarter worth about $718,000. State Street Corp purchased a new stake in shares of Predictive Oncology in the 2nd quarter worth about $391,000. Finally, Geode Capital Management LLC lifted its position in shares of Predictive Oncology by 198.4% in the 2nd quarter. Geode Capital Management LLC now owns 414,705 shares of the medical instruments supplier’s stock worth $543,000 after purchasing an additional 275,732 shares during the period. 8.13% of the stock is owned by hedge funds and other institutional investors.

Predictive Oncology Company Profile (NASDAQ:POAI)

Predictive Oncology Inc provides various healthcare products and services primarily in the United States. The company operates in three segments: Helomics, Soluble, and Skyline. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care.

Featured Article: Market Timing

Receive News & Ratings for Predictive Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Predictive Oncology and related companies with MarketBeat.com's FREE daily email newsletter.